The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -65.28%.However, over the last six months, we can see a stronger performance of -80.16%. Over the last 30 days, the price of CCCC has leaped by -41.59%. And in the last five days, it has surged by 3.31%.
C4 Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $7.66 on 07/16/24 and the lowest value was $1.09 on 04/17/25.
52-week price history of CCCC Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. C4 Therapeutics Inc’s current trading price is -83.68% away from its 52-week high, while its distance from the 52-week low is 15.21%. The stock’s price range during this period has varied between$1.09 and $7.66. The C4 Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.77 million for the day, a figure considerably higher than their average daily volume of 1.37 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
C4 Therapeutics Inc (CCCC) has experienced a quarterly decline of -67.62% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 88.74M and boasts a workforce of 110 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.0686, with a change in price of -2.8000. Similarly, C4 Therapeutics Inc recorded 1,550,911 in trading volume during the last 100 days, posting a change of -69.14%.
CCCC’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CCCC stands at 0.30. Similarly, the long-term debt-to-equity ratio is also 0.28.
CCCC Stock Stochastic Average
C4 Therapeutics Inc’s raw stochastic average for the past 50 days is presently 6.08%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 13.45%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 7.56% and 8.50%, respectively.
